AXIM - AXIM Biotechnologies, Inc.
| Previous Close | 1.96 |
| Open | 1.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 1.81 - 1.95 |
| 52 Week Range | 1.70 - 10.29 |
| Volume | 136,359 |
| Avg. Volume | 92,673 |
| Market Cap | 108.03M |
| Beta | -15.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•7 days ago
AXIM® Biotechnologies Signs LOI for Distribution of Products Throughout Australia and New Zealand
NEW YORK, Sept. 13, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed a Letter of Intent with Impression Healthcare Limited, ...
- GlobeNewswire•24 days ago
AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics
NEW YORK, Aug. 27, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that it has signed an exclusive distribution and license agreement with Revive ...
- GlobeNewswire•last month
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology-2018 (IDDST-2018), a conference focused on updating the breaking research of drug discovery and development for academic and industrial professionals, taking place in Cambridge, Mass. from August 16-19, 2018. AXIM’s Chief Technology Officer, Lekhram Changoer, will bring his expertise to this year’s event as a presenter on the topic of “Novel cGMP Technologies for Extraction, Purification, and Conversion of Cannabinoids for the Pharmaceutical Industry.” His presentation is scheduled to take place on Friday, August 17 from 3:30-3:50 p.m. ET in the Discovery Room, 3rd Floor as part of the Other Enabled Technologies for Drug Discovery session.
- GlobeNewswire•last month
Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced positive results from stability and dissolution tests performed on its prime drug candidate, MedChew Rx®, which will undergo clinical trials for the treatment of pain and spasticity in Multiple Sclerosis (MS) patients. Results showed that the primary Active Pharmaceutical Ingredients (APIs) in MedChew Rx™ remained stable throughout the test and that the availability of the APIs was greater than 90%. MedChew Rx® is comprised of the cannabinoid molecules delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which generally degrade after time.
- GlobeNewswire•3 months ago
AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
NEW YORK, June 28, 2018-- AXIM ® Biotechnologies, Inc., a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28 th Annual International ...
- Motley Fool•5 months ago
3 Things to Love and Hate About Medical Marijuana, Inc.'s Full-Year Report
It's another mixed bag for the first publicly traded pot stock in the U.S.
- Motley Fool•5 months ago
3 Marijuana Stocks You Couldn't Pay Me to Buy
These pot stocks are bad news for investors.
- Motley Fool•6 months ago
This Pot Stock Is Trading Below Its Book Value
Despite being an apparent book value bargain, this marijuana stock comes with big risks.
- Zacks Small Cap Research•6 months ago
AXIM Biotechnologies (AXIM) Advancing Multi-faceted Medical CBD and THC Pipeline
OTC:AXIM Summary • AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company ...
- PR Newswire•7 months ago
Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its major investment company AXIM® ...
- InvestorPlace•8 months ago
How to Make Some Green From Marijuana Stocks
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. Regrettably, CANN is losing more and more money on marijuana services every year and is also burning cash.
- Zacks Small Cap Research•8 months ago
An Opportunity in the Medical Cannabinoid Industry: AXIM Biotechnologies (AXIM)
• During the fourth quarter of 2017, cannabis stocks climbed sharply (North American Marijuana Index +137%) reflecting increased investor interest and positive fundamental tailwinds. • AXIM Biotechnologies is well positioned to benefit from the overall medical cannabinoid investment theme and is expected to achieve significant milestones during 2018. Making its debut on the Toronto Stock Exchange in April 2017, the Horizons Medical Marijuana Life Sciences ETF (HMMJ.TO) sought to mimic the North American Medical Marijuana Index, a basket of publicly-listed North American companies with significant business activities in the marijuana industry.
- CNW Group•9 months ago
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market
